Neuroleptic malignant syndrome |
Vital sign instability |
Requires exposure to newly started dopaminergic agent, or recent change in dose |
Altered mental status |
Low serum iron |
Elevated CPK |
Serotonin syndrome |
Altered mental status |
GI distress |
|
Rigidity |
Hyperreflexia |
|
Vital sign instability |
Clonus |
Delirium |
Hypoactive and hyperactive types |
Worsened by benzodiazepines |
Decreased attention |
Withdrawal from environment |
Other psychomotor abnormalities (echolalia, echopraxia, rigidity, etc.) not present |
Coma |
Hypoactivity |
Reflexes lost in coma |
|
Mutism |
Parakinetic symptoms not present |
|
Incontinence |
No response to benzodiazepine challenge |
Extrapyramidal side-effects (EPS) |
Akathisia |
No altered mental status |
Dystonia (may look like rigidity or posturing) |
No other motor symptoms present; no impaired volition |
No negativism |
Hypoactivity not present |
Parkinsonism |
Rigidity |
No other motor symptoms present |
|
Motor freezing |
Tremor present in Parkinsonism |
|
Staring |
Patients generally interactive |
Status epilepticus |
Immobility |
Specific EEG findings |
Withdrawal |